Standout Papers
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes (2007)
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma (2017)
Immediate Impact
9 by Nobel laureates 14 from Science/Nature 69 standout
Citing Papers
Type-I AIE Photosensitizer Loaded Biomimetic System Boosting Cuproptosis to Inhibit Breast Cancer Metastasis and Rechallenge
2023 Standout
Understanding and targeting resistance mechanisms in cancer
2023 Standout
Works of Frances A. Collichio being referenced
Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Frances A. Collichio | 2956 | 1368 | 986 | 1320 | 98 | 4.5k | |
| David W. Cescon | 2764 | 1690 | 621 | 1348 | 166 | 5.3k | |
| David S.P. Tan | 2409 | 2140 | 646 | 1421 | 165 | 4.9k | |
| Kimberly R. Kalli | 2012 | 2125 | 568 | 1079 | 100 | 5.3k | |
| Prudence A. Francis | 3207 | 874 | 543 | 1447 | 127 | 5.0k | |
| Tamar Safra | 3954 | 2412 | 1185 | 628 | 97 | 6.6k | |
| Stanley B. Kaye | 2524 | 3185 | 1183 | 937 | 102 | 6.0k | |
| Steve E. Kalloger | 1721 | 2646 | 536 | 1412 | 100 | 6.2k | |
| D. Killander | 2064 | 1895 | 590 | 1526 | 114 | 5.2k | |
| Paul DiSilvestro | 1885 | 1282 | 686 | 835 | 153 | 6.2k | |
| Hiroko Yamashita | 2561 | 2650 | 1220 | 1715 | 174 | 5.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...